Amphastar Q3 2026 net income rises to $37.8M
The board authorized a $50 million increase to the share buyback program, which is expected to continue for an indefinite period.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Amphastar Pharmaceuticals, Inc. (AMPH) reported third-quarter 2026 net revenues of $207.6 million, up 8% from $191.8 million a year earlier. GAAP net income was $37.8 million, compared with $17.4 million, and GAAP diluted EPS was $0.87 versus $0.37. Adjusted non-GAAP net income was $49.3 million, compared with $44.7 million, and adjusted non-GAAP diluted EPS was $1.14 versus $0.93. Gross profit was $99.6 million, and gross margin was 48.0%, compared with 51.4% a year earlier.
Cash flow provided by operating activities for the nine months ended September 30, 2026 was $142.5 million. On November 4, 2026, the board authorized a $50 million increase to the share buyback program, which is expected to continue for an indefinite period. Its stated primary goal is to offset dilution from equity compensation programs. Purchases may be made through the open market and private block transactions pursuant to Rule 10b5-1 plans, privately negotiated transactions, or other means; timing and actual repurchases depend on price, corporate and regulatory requirements, and other conditions.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointThird-quarter revenue increased 8% to $207.6 million year over year.
- Moderate pointThird-quarter GAAP net income was $37.8 million, versus $17.4 million a year earlier.
Negative
- None.
Filing Explained
For the nine months ended
8-K Event Classification
Key Figures
Key Terms
Adjusted non-GAAP net income financial
Rule 10b5-1 plans regulatory
abbreviated new drug application (ANDA) regulatory
biosimilar insulin candidate medical
mark-to-market adjustments financial
Earnings Snapshot
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were AMPH's third-quarter 2026 revenue and earnings?
What products are in AMPH's biosimilar and generic pipeline?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event Reported):
(Exact Name of Registrant as Specified in Charter)
(State or Other Jurisdiction of | (Commission File Number) | (I.R.S. Employer Identification |
(Address of Principal Executive Offices) | (Zip Code) |
Registrant's telephone number, including area code: (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||
The | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On November 5, 2026, Amphastar Pharmaceuticals, Inc. issued a press release announcing its financial results for the three months ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
Exhibit No. | | Description |
99.1 | Press release, dated November 5, 2026, issued by Amphastar Pharmaceuticals, Inc. | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 5, 2026 | Amphastar Pharmaceuticals, Inc. | ||
By: | /s/ WILLIAM J. PETERS | ||
William J. Peters | |||
Chief Financial Officer, Executive Vice President and Treasurer | |||
EXHIBIT 99.1
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026
| - | Net revenues of $207.6 million for the three months ended September 30, 2026 |
| - | GAAP net income of $37.8 million, or $0.87 per share, for the third quarter |
| - | Adjusted non-GAAP net income of $49.3 million, or $1.14 per share, for the third quarter |
| - | Company to hold a conference call today at 2:00 p.m. Pacific Time |
RANCHO CUCAMONGA, CA – November 5, 2026 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”), a biopharmaceutical company focused on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, today reported results for the three months ended September 30, 2026.
“Our third quarter results demonstrate the strength of Amphastar’s diversified portfolio and the commercial platform we have built. Record sales of BAQSIMI® and Primatene MIST®, together with contributions from recently launched products, supported continued revenue growth and further strengthened the foundation for our long-term strategy. During the quarter, we continued to advance programs across our complex generic, biosimilar, and proprietary pipelines while investing in the manufacturing, quality and development capabilities needed to support future growth. We remain focused on disciplined execution, strengthening our operations, and deploying capital in ways that we believe can create sustainable long-term value for our shareholders,” said Dr. Jack Zhang, Amphastar’s President and Chief Executive Officer.
| | Three Months Ended | | Nine Months Ended | ||||||||
| | September 30, | | September 30, | ||||||||
| | 2026 | | 2025 | | 2026 | | 2025 | ||||
| | (in thousands, except per share data) | ||||||||||
Net revenues | | $ | 207,608 | | $ | 191,840 | | $ | 562,682 | | $ | 536,782 |
GAAP net income | | $ | 37,763 | | $ | 17,350 | | $ | 74,531 | | $ | 73,665 |
Adjusted non-GAAP net income* | | $ | 49,265 | | $ | 44,696 | | $ | 109,502 | | $ | 122,460 |
GAAP diluted EPS | | $ | 0.87 | | $ | 0.37 | | $ | 1.67 | | $ | 1.52 |
Adjusted non-GAAP diluted EPS* | | $ | 1.14 | | $ | 0.93 | | $ | 2.45 | | $ | 2.52 |
* Adjusted non-GAAP net income and adjusted non-GAAP diluted EPS are non-GAAP financial measures. Please see the discussion in the section entitled “Non-GAAP Financial Measures” and the reconciliation of GAAP to non-GAAP financial measures in Table III of this press release.
Third Quarter Results
| | Three Months Ended | | | | | | | ||||
| | September 30, | | Change | | |||||||
| | 2026 | | 2025 | | Dollars | | % | | |||
| | (in thousands) | | | | |||||||
Net revenues: | | | | | | | | | | | | |
BAQSIMI® | | $ | 58,804 | | $ | 53,608 | | $ | 5,196 | | 10 | % |
Primatene MIST® | | | 31,461 | | | 28,808 | | | 2,653 | | 9 | % |
Lidocaine | | | 16,638 | | | 12,932 | | | 3,706 | | 29 | % |
Epinephrine | | | 15,273 | | | 18,789 | | | (3,516) | | (19) | % |
Glucagon | | | 8,575 | | | 13,558 | | | (4,983) | | (37) | % |
Ipratropium bromide | | | 6,645 | | | — | | | 6,645 | | N/A | |
Other products | |
| 70,212 | |
| 64,145 | |
| 6,067 |
| 9 | % |
Total net revenues | | $ | 207,608 | | $ | 191,840 | | $ | 15,768 | | 8 | % |
Changes in net revenues as compared to the third quarter of the prior year were primarily driven by:
| ● | BAQSIMI® sales increased primarily due to an increase in unit volumes, contributing $7.4 million in sales driven by our continued marketing efforts. This increase was partially offset by a lower average selling price, as a result of a change in gross-to-net discounts due to changes in chargebacks and rebates and changes to the customer mix, impacting sales of approximately $2.2 million. |
| ● | Primatene MIST® sales increased due to a higher average selling price, contributing $1.6 million in sales, as a result of a price increase that went into effect in the second quarter of 2026, and an increase in unit volumes, contributing $1.0 million in sales, as in-store demand for Primatene MIST® continues to grow. |
| ● | Lidocaine sales increased primarily due to an increase in unit volumes as a result of an increase in demand caused by other supplier shortages. |
| ● | Ipratropium bromide continued to have strong sales during the quarter, following our launch in the second quarter of 2026. |
| ● | Epinephrine sales decreased primarily due to lower unit volumes of our pre-filled syringe product, resulting from slower product releases associated with ongoing remediation efforts at our subsidiary, International Medication Systems, Limited (“IMS”). |
| ● | Glucagon sales decreased primarily due to a lower average selling price, as a result of increased competition. |
| ● | Other pharmaceutical product sales increased primarily due to sales of teriparatide of $6.4 million, which we launched in December 2025. Additionally, API sales from our subsidiary, Amphastar Nanjing Pharmaceuticals, Inc. (“ANP”), contributed $6.2 million. These increases were partially offset by a decrease in sales of several products manufactured at our IMS facility due to ongoing remediation activities. |
| | Three Months Ended | | | | | | | ||||
| | September 30, | | Change | | |||||||
| | 2026 | | 2025 | | Dollars | | % | | |||
| | (in thousands) | | | | |||||||
Net revenues | | $ | 207,608 | | $ | 191,840 | | $ | 15,768 | | 8 | % |
Cost of revenues | | | 107,979 | | | 93,194 | | | 14,785 | | 16 | % |
Gross profit | | $ | 99,629 | | $ | 98,646 | | $ | 983 | | 1 | % |
as % of net revenues | | | 48.0% | | | 51.4% | | | | | | |
Changes in the cost of revenues and gross margin were primarily driven by:
| ● | The impact of lower average selling price for BAQSIMI®, glucagon, and our epinephrine multi-dose vial product, which are higher margin products. |
| ● | Increased manufacturing expenses as a result of remediation efforts at our IMS facility in response to the FDA warning letter, as well as the expansion of our manufacturing facility in Rancho Cucamonga, CA. |
| ● | This was partially offset by our recently launched products, including teriparatide and ipratropium bromide, both of which are higher-margin products. |
| | Three Months Ended | | | | | | | ||||
| | September 30, | | Change | | |||||||
| | 2026 | | 2025 | | Dollars | | % | | |||
| | (in thousands) | | | | |||||||
Selling, distribution, and marketing | | $ | 11,934 | | $ | 11,505 | | $ | 429 | | 4 | % |
General and administrative | | | 16,844 | | | 39,467 | | | (22,623) | | (57) | % |
Research and development | | | 20,078 | | | 22,354 | | | (2,276) | | (10) | % |
| ● | Selling, distribution, and marketing expenses increased primarily due to increased freight expense. |
| ● | General and administrative expenses decreased primarily due to a litigation provision of $23.1 million that was recorded in the third quarter of 2025 for a litigation matter that was settled in the fourth quarter of 2025. |
| ● | Research and development expenses decreased primarily due to the $5.3 million upfront payment for the licensing agreement that we entered into with Nanjing Anji Biotechnology Co., Ltd. in the third quarter of 2025. This decrease was partially offset by an increase in material and supply expenses, primarily for our insulin and proprietary pipeline products, as well as an increase in salary and personnel-related expenses. |
| | Three Months Ended | | | | | | | ||||
| | September 30, | | Change | | |||||||
| | 2026 | | 2025 | | Dollars | | % | | |||
| | (in thousands) | | | | |||||||
Non-operating expenses: | | | | | | | | | | | | |
Interest income | | $ | 2,287 | | $ | 2,246 | | $ | 41 | | 2 | % |
Interest expense | | | (6,760) | | | (6,284) | | | (476) | | 8 | % |
Other income (expenses), net | | | 2,764 | | | 231 | | | 2,533 | | NM | |
Total non-operating expenses, net | | $ | (1,709) | | $ | (3,807) | | $ | 2,098 | | (55) | % |
The change in non-operating expenses, net, is primarily a result of foreign currency fluctuation, as well as the mark-to-market adjustments relating to our interest rate swap contract during the three months ended September 30, 2026.
Cash flow provided by operating activities for the nine months ended September 30, 2026, was $142.5 million.
Share Buyback Program
On November 4, 2026, the Company’s Board of Directors authorized a $50 million increase to the Company’s share buyback program, which is expected to continue for an indefinite period of time. The primary goal of the program is to offset dilution created by the Company’s equity compensation programs.
Purchases may be made through the open market and private block transactions pursuant to Rule 10b5-1 plans, privately negotiated transactions, or other means, as determined by the Company’s management and in accordance with the requirements of the Securities and Exchange Commission and applicable laws.
The timing and actual number of shares repurchased will depend on a variety of factors including price, corporate and regulatory requirements, and other conditions.
Pipeline Information
The Company currently has one abbreviated new drug application (“ANDA”) and one biosimilar insulin candidate filed with the FDA for products targeting a combined market size exceeding $1.6 billion, along with two biosimilar products in development targeting a market size exceeding $3.5 billion, and three generic products in development targeting a market size of over $1.2 billion. This market information is based on IQVIA data for the 12 months ended September 30, 2026, supplemented by data provided by the branded company for one of the generic targets. The Company is developing multiple proprietary products with injectable, topical and intranasal dosage forms.
The Company’s proprietary pipeline also includes four in-licensed products including three proprietary peptides targeting oncology and ophthalmology indications, and a fully synthetic corticotropin compound designed to address inflammatory and autoimmune conditions.
Conference Call Information
The Company will hold a conference call to discuss its financial results today, November 5, 2026, at 2:00 p.m. Pacific Time.
To access the conference call, dial toll-free (877) 407-0989 or (201) 389-0921 for international callers, ten minutes before the conference.
The call can also be accessed on the Investors page on the Company’s website at www.amphastar.com.
Non-GAAP Financial Measures
To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles (“GAAP”), the Company is disclosing non-GAAP financial measures when providing financial results. The Company believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to
financial measures prepared only in accordance with GAAP. As a result, the Company is disclosing certain non-GAAP results, including (i) Adjusted non-GAAP net income (loss) and (ii) Adjusted non-GAAP diluted EPS, which generally exclude amortization expense, share-based compensation, impairment charges, certain debt issuance costs, legal settlements, and other one-time events in order to supplement investors’ and other readers’ understanding and assessment of the Company’s financial performance because the Company’s management uses these measures internally for forecasting, budgeting, and measuring its operating performance. Whenever the Company uses such non-GAAP measures, it will provide a reconciliation of non-GAAP financial measures to their most directly comparable GAAP financial measures. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most directly comparable GAAP measures set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP.
Market Data
This press release contains market data that we obtained from industry sources. These sources do not guarantee the accuracy or completeness of the information. Although we believe that our industry sources are reliable, we do not independently verify the information. The market data may include projections that are based on a number of other projections. While we believe these assumptions to be reasonable and sound as of the date of this press release, actual results may differ from the projections.
About Amphastar Pharmaceuticals, Inc.
Amphastar is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient, or API products. Most of the Company’s finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. More information and resources are available at www.amphastar.com.
Amphastar’s logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar®, BAQSIMI®, Primatene MIST®, Amphadase®, and Cortrosyn®, are the property of Amphastar.
Forward-Looking Statements
All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth and our ability to continue to scale, sales and marketing of our products, market size and expansion, product portfolio, product development, our deployment of capital, the timing of FDA filings or approvals, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the impact of our products, including their potential for continued revenue growth, the strategic trajectory of and market for our product pipeline, our long-term strategy, our ability to leverage our existing expertise and technology, the impacts of any licensing agreements and ability to commercialize additional therapies, our in-house manufacturing expertise, our ability to create value for our shareholders, our ability to deliver high-quality, affordable therapies to patients, our commercial momentum and position in the market. These statements are not facts but rather are based on Amphastar’s historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as “may,” “might,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar’s control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar’s filings with the Securities and Exchange Commission (“SEC”), including in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 26, 2026, in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 7, 2026, in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 6, 2026, in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the SEC on November 5, 2026, and our other filings or reports that we may file with the SEC. You can locate these reports through our website at http://ir.amphastar.com and on the SEC’s website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar
undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.
Contact Information:
Amphastar Pharmaceuticals, Inc.
Bill Peters
Chief Financial Officer
(909) 476-3416
Table I
Amphastar Pharmaceuticals, Inc.
Condensed Consolidated Statement of Operations
(Unaudited; in thousands, except per share data)
| | Three Months Ended | | Nine Months Ended | ||||||||
| | September 30, | | September 30, | ||||||||
| | 2026 | | 2025 | | 2026 | | 2025 | ||||
Net revenues | | $ | 207,608 | | $ | 191,840 | | $ | 562,682 | | $ | 536,782 |
Cost of revenues | |
| 107,979 | | | 93,194 | | | 299,261 | | | 266,395 |
Gross profit | |
| 99,629 | |
| 98,646 | |
| 263,421 | |
| 270,387 |
| | | | | | | | | | | | |
Operating expenses: | | | | | | | | | | | | |
Selling, distribution, and marketing | |
| 11,934 | | | 11,505 | | | 37,196 | | | 33,606 |
General and administrative | |
| 16,844 | | | 39,467 | | | 53,114 | | | 69,454 |
Research and development | |
| 20,078 | | | 22,354 | | | 68,979 | | | 62,530 |
Total operating expenses | |
| 48,856 | |
| 73,326 | |
| 159,289 | |
| 165,590 |
| | | | | | | | | | | | |
Income from operations | |
| 50,773 | |
| 25,320 | |
| 104,132 | |
| 104,797 |
| | | | | | | | | | | | |
Non-operating expenses: | | | | | | | | | | | | |
Interest income | | | 2,287 | | | 2,246 | | | 6,974 | | | 6,256 |
Interest expense | | | (6,760) | | | (6,284) | | | (19,972) | | | (18,851) |
Other income (expenses), net | | | 2,764 | | | 231 | | | 6,526 | | | (492) |
Total non-operating expenses, net | |
| (1,709) | | | (3,807) | | | (6,472) | | | (13,087) |
| | | | | | | | | | | | |
Income before income taxes | |
| 49,064 | |
| 21,513 | |
| 97,660 | |
| 91,710 |
Income tax provision | |
| 11,301 | | | 4,163 | | | 23,129 | | | 18,045 |
| | | | | | | | | | | | |
Net income | | $ | 37,763 | | $ | 17,350 | | $ | 74,531 | | $ | 73,665 |
| | | | | | | | | | | | |
Net income per share: | | | | | | | | | | | | |
Basic | | $ | 0.89 | | $ | 0.38 | | $ | 1.70 | | $ | 1.57 |
Diluted | | $ | 0.87 | | $ | 0.37 | | $ | 1.67 | | $ | 1.52 |
| | | | | | | | | | | | |
Weighted-average shares used to compute net income per share: | | | | | | | | | | | | |
Basic | | | 42,579 | | | 46,474 | | | 43,848 | | | 47,021 |
Diluted | | | 43,377 | | | 47,677 | | | 44,687 | | | 48,565 |
Table II
Amphastar Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
(in thousands, except per share data)
| | September 30, | | December 31, | ||
| | 2026 | | 2025 | ||
| | (unaudited) | | | | |
ASSETS | | | | | | |
Current assets: | | | | | | |
Cash and cash equivalents | | $ | 204,588 | | $ | 170,177 |
Restricted cash | | | 235 | | | 235 |
Short-term investments | | | 26,046 | | | 112,635 |
Restricted short-term investments | |
| 2,200 | | | 2,200 |
Accounts receivable, net | |
| 182,215 | | | 143,560 |
Inventories | |
| 173,920 | | | 176,890 |
Income tax refunds and deposits | |
| 2,532 | | | 17,167 |
Prepaid expenses and other assets | |
| 10,949 | | | 13,152 |
Total current assets | |
| 602,685 | |
| 636,016 |
| | | | | | |
Property, plant, and equipment, net | |
| 312,871 | | | 310,567 |
Finance lease right-of-use assets | | | 120 | | | 221 |
Operating lease right-of-use assets | | | 75,055 | | | 42,931 |
Goodwill and intangible assets, net | |
| 640,429 | | | 565,965 |
Other assets | |
| 38,100 | | | 31,135 |
Deferred tax assets | |
| 42,464 | | | 42,464 |
Total assets | | $ | 1,711,724 | | $ | 1,629,299 |
| | | | | | |
LIABILITIES AND STOCKHOLDERS' EQUITY | | | | | | |
Current liabilities: | | | | | | |
Accounts payable and accrued liabilities | | $ | 168,068 | | $ | 148,348 |
Income taxes payable | |
| 2,143 | |
| 239 |
Current portion of long-term debt | |
| 2,505 | |
| 1,641 |
Current portion of operating lease liabilities | | | 8,718 | | | 7,928 |
Total current liabilities | |
| 181,434 | |
| 158,156 |
| | | | | | |
Long-term reserve for income tax liabilities | |
| 5,926 | | | 5,926 |
Long-term debt, net of current portion and unamortized debt issuance costs | |
| 610,497 | | | 608,749 |
Long-term operating lease liabilities, net of current portion | | | 69,969 | | | 37,684 |
Other long-term liabilities | |
| 29,344 | | | 29,979 |
Total liabilities | |
| 897,170 | |
| 840,494 |
Commitments and contingencies | | | | | | |
Stockholders’ equity: | | | | | | |
Preferred stock: par value $0.0001; 20,000,000 shares authorized; no shares issued and outstanding | |
| — | |
| — |
Common stock: par value $0.0001; 300,000,000 shares authorized; 62,441,273 and 42,648,323 shares issued and outstanding, respectively, as of September 30, 2026 and 61,779,883 and 45,645,497 shares issued and outstanding, respectively, as of December 31, 2025 | |
| 6 | | | 6 |
Additional paid-in capital | |
| 562,145 | | | 535,380 |
Retained earnings | |
| 741,412 | | | 666,881 |
Accumulated other comprehensive loss | |
| (6,020) | | | (5,314) |
Treasury stock | |
| (482,989) | | | (408,148) |
Total stockholders' equity | | | 814,554 | | | 788,805 |
Total liabilities and stockholders’ equity | | $ | 1,711,724 | | $ | 1,629,299 |
Table III
Amphastar Pharmaceuticals, Inc.
Reconciliation of Non-GAAP Measures
(Unaudited; in thousands, except per share data)
| | Three Months Ended | | Nine Months Ended | ||||||||
| | September 30, | | September 30, | ||||||||
| | 2026 | | 2025 | | 2026 | | 2025 | ||||
| | | | | | | | | | | | |
GAAP net income | | $ | 37,763 | | $ | 17,350 | | $ | 74,531 | | $ | 73,665 |
Adjusted for: | | | | | | | | | | | | |
Intangible asset amortization | |
| 7,394 | |
| 6,269 | |
| 19,933 | |
| 18,778 |
Share-based compensation | |
| 7,007 | |
| 6,297 | |
| 23,371 | |
| 21,072 |
Impairment of long-lived assets | |
| 436 | |
| — | |
| 436 | |
| — |
Litigation provision | | | — | | | 23,147 | | | 1,000 | | | 23,147 |
Income tax provision on pre-tax adjustments | |
| (3,335) | |
| (8,367) | |
| (9,769) | |
| (14,202) |
Adjusted non-GAAP net income | | $ | 49,265 | | $ | 44,696 | | $ | 109,502 | | $ | 122,460 |
| | | | | | | | | | | | |
Adjusted non-GAAP net income per share: | | | | | | | | | | | | |
Basic | | $ | 1.16 | | $ | 0.96 | | $ | 2.50 | | $ | 2.60 |
Diluted | | $ | 1.14 | | $ | 0.93 | | $ | 2.45 | | $ | 2.52 |
| | | | | | | | | | | | |
Weighted-average shares used to compute adjusted non-GAAP net income per share: | | | | | | | | | | | | |
Basic | |
| 42,579 | |
| 46,474 | |
| 43,848 | |
| 47,021 |
Diluted | |
| 43,377 | |
| 47,677 | |
| 44,687 | |
| 48,565 |
| | Three Months Ended September 30, 2026 | |||||||||||||
| | | | | | | | | | | |||||
| | | | Selling, | | General | | Research | | | |||||
| | Cost of | | distribution | | and | | and | | Income | |||||
| | revenue | | and marketing | | administrative | | development | | tax provision | |||||
GAAP | | $ | 107,979 | | $ | 11,934 | | $ | 16,844 | | $ | 20,078 | | $ | 11,301 |
Intangible asset amortization | | | (7,373) | | | — | | | (1) | | | (20) | | | — |
Share-based compensation | | | (1,408) | | | (348) | | | (4,586) | | | (665) | | | — |
Impairment of long-lived assets | | | (436) | | | — | | | — | | | — | | | — |
Income tax provision on pre-tax adjustments | | | — | | | — | | | — | | | — | | | 3,335 |
Non-GAAP | | $ | 98,762 | | $ | 11,586 | | $ | 12,257 | | $ | 19,393 | | $ | 14,636 |
| | Three Months Ended September 30, 2025 | |||||||||||||
| | | | | | | | | | | |||||
| | | | Selling, | | General | | Research | | | |||||
| | Cost of | | distribution | | and | | and | | Income | |||||
| | revenue | | and marketing | | administrative | | development | | tax provision | |||||
GAAP | | $ | 93,194 | | $ | 11,505 | | $ | 39,467 | | $ | 22,354 | | $ | 4,163 |
Intangible asset amortization | | | (6,248) | | | — | | | (1) | | | (20) | | | — |
Share-based compensation | | | (1,274) | | | (301) | | | (4,140) | | | (582) | | | — |
Litigation provision | | | — | | | — | | | (23,147) | | | — | | | — |
Income tax provision on pre-tax adjustments | | | — | | | — | | | — | | | — | | | 8,367 |
Non-GAAP | | $ | 85,672 | | $ | 11,204 | | $ | 12,179 | | $ | 21,752 | | $ | 12,530 |
| | Nine Months Ended September 30, 2026 | |||||||||||||
| | | | | | | | | | | |||||
| | | | Selling, | | General | | Research | | | |||||
| | Cost of | | distribution | | and | | and | | Income | |||||
| | revenue | | and marketing | | administrative | | development | | tax provision | |||||
GAAP | | $ | 299,261 | | $ | 37,196 | | $ | 53,114 | | $ | 68,979 | | $ | 23,129 |
Intangible asset amortization | | | (19,873) | | | — | | | (2) | | | (58) | | | — |
Share-based compensation | | | (5,421) | | | (1,067) | | | (14,236) | | | (2,647) | | | — |
Impairment of long-lived assets | | | (436) | | | — | | | — | | | — | | | — |
Litigation provision | | | — | | | — | | | (1,000) | | | — | | | — |
Income tax provision on pre-tax adjustments | | | — | | | — | | | — | | | — | | | 9,769 |
Non-GAAP | | $ | 273,531 | | $ | 36,129 | | $ | 37,876 | | $ | 66,274 | | $ | 32,898 |
| | Nine Months Ended September 30, 2025 | |||||||||||||
| | | | | | | | | | | |||||
| | | | Selling, | | General | | Research | | | |||||
| | Cost of | | distribution | | and | | and | | Income | |||||
| | revenue | | and marketing | | administrative | | development | | tax provision | |||||
GAAP | | $ | 266,395 | | $ | 33,606 | | $ | 69,454 | | $ | 62,530 | | $ | 18,045 |
Intangible asset amortization | | | (18,718) | | | — | | | (2) | | | (58) | | | — |
Share-based compensation | | | (5,012) | | | (925) | | | (12,777) | | | (2,358) | | | — |
Litigation provision | | | — | | | — | | | (23,147) | | | — | | | — |
Income tax provision on pre-tax adjustments | | | — | | | — | | | — | | | — | | | 14,202 |
Non-GAAP | | $ | 242,665 | | $ | 32,681 | | $ | 33,528 | | $ | 60,114 | | $ | 32,247 |